29D1 Kraft, Walter - Thomas Jefferson University - Thomas Jefferson University
wxk001

Walter K. Kraft, MD

Contact Dr. Kraft

132 South Tenth Street
1170 Main Building
Philadelphia, PA 19107

(215) 955-9077
(215) 955-5681 fax

Most Recent Peer-reviewed Publications

  1. Pharmacologic and clinical evaluation of posaconazole
  2. Population Pharmacokinetic Model of Sublingual Buprenorphine in Neonatal Abstinence Syndrome
  3. Ethanol Pharmacokinetics in Neonates and Infants
  4. Posaconazole tablet pharmacokinetics: Lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects
  5. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: Safety, antiviral activity, resistance, and pharmacokinetics
  6. Poor positive predictive value of McConnell's sign on transthoracic echocardiography for the diagnosis of acute pulmonary embolism.
  7. Cardiovascular protection to improve clinical outcomes after subarachnoid hemorrhage: Is there a proven role?
  8. MK-0448, a specific Kv1.5 inhibitor safety, pharmacokinetics, and pharmacodynamic electrophysiology in experimental animal models and humans
  9. Limited Sampling Estimates of Epigallocatechin Gallate Exposures in Cirrhotic and Noncirrhotic Patients With Hepatitis C After Single Oral Doses of Green Tea Extract
  10. Pharmacologic Management of the Opioid Neonatal Abstinence Syndrome
  11. Pharmacokinetics and pharmacodynamics of MK-5046, a bombesin receptor subtype-3 (BRS-3) agonist, in healthy patients
  12. Model for End-Stage Liver Disease score for predicting outcome in critically ill medical patients with liver cirrhosis
  13. Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease
  14. Healthy volunteer registries and ethical research principles
  15. The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus
  16. Single- and multiple-ascending-dose studies of the NS3 protease inhibitor asunaprevir in subjects with or without chronic hepatitis C
  17. Prevalence of obstructive lung disease in HIV population: A cross sectional study
  18. The effects of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin
  19. Prophylaxis for Deep Vein Thrombosis and Pulmonary Embolism in the Surgical Patient
  20. The incidence of deep vein thrombosis detected by routine surveillance ultrasound in neurosurgery patients receiving dual modality prophylaxis
0